Skip to Content

'
Anita L. Sabichi, M.D.

Present Title & Affiliation

Primary Appointment

Associate Professor (primary appointment), Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Associate Professor (joint appointment), Department of Clinical Cancer Prevention, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Research Interests

Optimizing cancer prevention and combined therapy regimens, and biology of head and neck cancer.

Clinical Interests

Interdisciplinary management of head and neck cancer, chemoprevention of head and neck cancer

Office Address

The University of Texas M. D. Anderson Cancer Center
P. O. Box 301402
Department of Thoracic/Head and Neck Medical Oncology
Unit Number: 432
Houston, TX 77230-1402
Room Number: FC9.2058
Phone: (713) 792-6363
Fax: (713) 792-1220
Email: asabichi@mdanderson.org

Education & Training

Degree-Granting Education

1987 University of Colorado School of Medicine, Denver, CO, MD, Doctor of Medicine
1981 University of Colorado, Denver, CO, BA, B.A., w/distinction, Molecular & Cellular Biology

Postgraduate Training

7/1993-5/1997 Research Associate, National Cancer Institute, Division of Clinical Sciences, Medicine Branch, Rockville, MD
7/1990-6/1993 Clinical Fellowship, Medical Oncology, National Cancer Institute, Division of Clinical Sciences, Medicine Branch, Bethesda, MD
7/1988-6/1990 Clinical Residency, Internal Medicine, Columbia Presbyterian Medical Center, Presbyterian Hospital, New York, NY
7/1987-6/1988 Clinical Internship, Internal Medicine, Presbyterian Hospital Columbia Presbyterian Medical Center, New York, NY

Selected Publications

Peer-Reviewed Original Research Articles
1. McGovern SL, Williams MD, Weber RS, Sabichi A, Chambers MS, Martin JW, Chao KS. Three synchronous HPV-associated squamous cell carcinomas of Waldeyer's ring: Case report and comparison with Slaughter's model of field cancerization. Head Neck. e-Pub 7/2009. PMID: 19572386.
2. Chiong E, Dadbin A, Harris LD, Sabichi AL, Grossman HB. The Use of Short Tandem Repeat Profiling to Characterize Human Bladder Cancer Cell Lines. J Urol 181(6), 6/2009. e-Pub 4/2009. PMID: 19375735.
3. William WN, Lee JJ, Lippman SM, Martin JW, Chakravarti N, Tran HT, Sabichi AL, Kim ES, Feng L, Lotan R, Papadimitrakopoulou VA. High-dose fenretinide in oral leukoplakia. Cancer Prev Res (Phila Pa) 2(1):22-6, 1/2009. PMID: 19139014.
4. Gee J, Lee IL, Grossman HB, Sabichi AL. Forced COX-2 expression induces PGE(2) and invasion in immortalized urothelial cells. Urol Oncol 26(6):641-5, Nov-Dec, 11/2008. e-Pub 1/2008. PMID: 18367112.
5. Harris LD, De La Cerda J, Tuziak T, Rosen D, Xiao L, Shen Y, Sabichi AL, Czerniak B, Grossman HB. Analysis of the expression of biomarkers in urinary bladder cancer using a tissue microarray. Mol Carcinog 47(9):678-85, 9/2008. PMID: 18288642.
6. Cooksley CD, Avritscher EB, Grossman HB, Sabichi AL, Dinney CP, Pettaway C, Elting LS. Clinical Model of Cost of Bladder Cancer in the Elderly. Urology 71(3):519-525, 3/2008. PMID: 18342201.
7. Sabichi AL, Lerner SP, Atkinson EN, Grossman HB, Caraway NP, Dinney CP, Penson DF, Matin S, Kamat A, Pisters LL, Lin DW, Katz RL, Brenner DE, Hemstreet GP, Wargo M, Bleyer A, Sanders WH, Clifford JL, Parnes HL, Lippman SM. Phase III Prevention Trial of Fenretinide in Patients with Resected Non-Muscle-Invasive Bladder Cancer. Clin Cancer Res 14:1(1):224-229, 1/2008. PMID: 18172274.
8. Brewster AM, Lee JJ, Clayman GL, Clifford JL, Reyes MJ, Zhou X, Sabichi AL, Strom SS, Collins R, Meyers CA, Lippman SM. Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma. J Clin Oncol 25(15):1974-8, 5/2007. PMID: 17513803.
9. Avritscher EB, Cooksley CD, Grossman HB, Sabichi AL, Hamblin L, Dinney CP, Elting LS. Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology 68(3):549-53, Jul-Aug, 9/2006. PMID: 16979735.
10. Cárdenas-Turanzas M, Cooksley C, Pettaway CA, Sabichi AL, Grossman HB, Elting L. Comparative outcome of bladder cancer. Obstet Gynecol 108(1):169-175, Jul-Aug, 7/2006. PMID: 16816072.
11. Subbarayan V, Krieg P, Hsi LC, Kim J, Yang P, Sabichi AL, Llansa N, Mendoza G, Logothetis CJ, Newman RA, Lippman SM, Menter DG. 15-Lipoxygenase-2 gene regulation by its product 15-(S)-hydroxyeicosatetraenoic acid through a negative feedback mechanism that involves peroxisome proliferator-activated receptor gamma. Oncogene 25(44):6015-25, 5/2006. PMID: 16682954.
12. Sabichi AL, Lee JJ, Taylor RJ, Thompson IM, Miles BJ, Tangen CM, Minasian LM, Pisters LL, Caton JR, Basler JW, Lerner SP, Menter DG, Marshall JR, Crawford ED, Lippman SM. Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group Study. Clin Cancer Res 12(7 Pt 1):2178-84, Jul-Aug, 4/2006. PMID: 16609032.
13. Sabichi AL, Keyhani A, Tanaka N, Delacerda J, Lee IL, Zou C, Zhou JH, Benedict WF, Grossman HB. Characterization of a panel of cell lines derived from urothelial neoplasms: genetic alterations, growth in vivo and the relationship of adenoviral mediated gene transfer to coxsackie adenovirus receptor expression. J Urol 175(3 Pt 1):1133-7, Jul-Aug, 3/2006. PMID: 16469639.
14. Gee J, Lee IL, Jendiroba D, Fischer SM, Grossman HB, Sabichi AL. Selective cyclooxygenase-2 inhibitors inhibit growth and induce apoptosis of bladder cancer. Oncol Rep 15(2):471-477, Jul-Aug, 2/2006. PMID: 16391871.
15. Kim J, Sun P, Lam YW, Troncoso P, Sabichi AL, Babaian RJ, Pisters LL, Pettaway CA, Wood CG, Lippman SM, McDonnell TJ, Lieberman R, Logothetis C, Ho SM. Changes in serum proteomic patterns by presurgical alpha-tocopherol and L-selenomethionine supplementation in prostate cancer. Cancer Epidemiol Biomarkers Prev 14(7):1697-702, Jul-Aug, 7/2005. PMID: 16030104.
16. Kim J, Yang P, Suraokar M, Sabichi AL, Llansa ND, Mendoza G, Subbarayan V, Logothetis CJ, Newman RA, Lippman SM, Menter DG. Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products. Cancer Res 65(14):6189-98, Jul-Aug, 7/2005. PMID: 16024620.
17. Subbarayan V, Xu XC, Kim J, Yang P, Hoque A, Sabichi AL, Llansa N, Mendoza G, Logothetis CJ, Newman RA, Lippman SM, Menter DG. Inverse relationship between 15-lipoxygenase-2 and PPAR-gamma gene expression in normal epithelia compared with tumor epithelia. Neoplasia 7(3):280-93, Jul-Aug, 3/2005. PMID: 15799828.
18. Klein RD, Van Pelt CS, Sabichi AL, Dela Cerda J, Fischer SM, Fürstenberger G, Müller-Decker K. Transitional cell hyperplasia and carcinomas in urinary bladders of transgenic mice with keratin 5 promoter-driven cyclooxygenase-2 overexpression. Cancer Res 65(5):1808-13, Jul-Aug, 3/2005. PMID: 15753378.
19. Subbarayan V, Sabichi AL, Kim J, Llansa N, Logothetis CJ, Lippman SM, Menter DG. Differential peroxisome proliferator-activated receptor-gamma isoform expression and agonist effects in normal and malignant prostate cells. Cancer Epidemiol Biomarkers Prev 13(11 Pt 1):1710-6, Jul-Aug, 11/2004. PMID: 15533897.
20. Sabichi AL, Subbarayan V, Llansa N, Lippman SM, Menter DG. Peroxisome proliferator-activated receptor-gamma suppresses cyclooxygenase-2 expression in human prostate cells. Cancer Epidemiol Biomarkers Prev 13(11 Pt 1):1704-9, Jul-Aug, 11/2004. PMID: 15533896.
21. Dinney CP, McConkey DJ, Millikan RE, Wu X, Bar-Eli M, Adam L, Kamat AM, Siefker-Radtke AO, Tuziak T, Sabichi AL, Grossman HB, Benedict WF, Czerniak B. Focus on bladder cancer. Cancer Cell 6(2):111-6, Jul-Aug, 8/2004. PMID: 15324694.
22. Sabichi AL, Lippman SM. COX-2 inhibitors and other nonsteroidal anti-inflammatory drugs in genitourinary cancer. Semin Oncol 31(2 Suppl 7):36-44, Jul-Aug, 4/2004. PMID: 15179622.
23. Salas TR, Kim J, Vakar-Lopez F, Sabichi AL, Troncoso P, Jenster G, Kikuchi A, Chen SY, Shemshedini L, Suraokar M, Logothetis CJ, DiGiovanni J, Lippman SM, Menter DG. Glycogen synthase kinase-3 beta is involved in the phosphorylation and suppression of androgen receptor activity. J Biol Chem 279(18):19191-200, Jul-Aug, 4/2004. PMID: 14985354.

Last updated: 8/18/2009